Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to Pliant Therapeutics' INTEGRIS-PSC Phase 2a Trial 320 milligram. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a call.
(Operator Instructions) Please be advised that today's conference is being recorded. I would like now to turn the conference over to Christopher Keenan, Vice President of Investor Relations. Please go ahead.
Thank you, Michelle, and good morning, everyone. Thank you for joining us for Pliant's presentation of top-line data from the 320 mg dose group of INTEGRIS-PSC, our Phase 2a clinical trial evaluating bexotegrast, previously known as PLN-74809 in patients with primary sclerosing cholangitis. The press release that we will be referencing today is available under the Investors and Media section of our corporate website. A replay of this event and the slides accompanying this webcast will be available in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |